Eylea, an injection against the leading causes of blindness among the elderly, is currently approved in the EU for treatment intervals of up to five months. Bayer has developed it jointly with Regeneron. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/bayer-secures-eu-approval-for-longer-eylea-treatment-intervals-against-blindness/121360513